Introgen wins European patent decision on p53 gene therapeutic

Introgen Therapeutics has announced that it was successful in winning the decision regarding its opposition of European Patent 0 390 323 before the European Patent Office (EPO) in which all claims directed to therapeutic applications of the p53 gene, the active component of Introgen's Advexin molecular therapy, were finally revoked by the ...

Continue to Introgen wins European patent decision on p53 gene therapeutic on News-Medical News Feed.

Medical Buzz delivers the most recent headlines from the medical world. Diseases, cures, accidents, medicin. Click below for more headlines ...
Medical buzz